Patents by Inventor Silvia Vailati

Silvia Vailati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSOCIATIONS OF FOSFOMYCIN AND COLISTIN FOR USE AGAINST BIOFILM-ASSOCIATED BACTERIAL INFECTIONS
    Publication number: 20240148822
    Abstract: The present invention relates to a synergistic pharmacological antibiofilm association of colistin and fosfomycin for use in the treatment of a bacterial infection caused by a biofilm-forming pathogen selected from A. baumannii, P. aeruginosa, S. maltophilia and K. pneumoniae strains, preferably in the biofilm phase of growth and, in particular infections associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising CF, NCFB and COPD, especially in hospitalized patients.
    Type: Application
    Filed: March 7, 2022
    Publication date: May 9, 2024
    Applicant: Zambon S.P.A.
    Inventors: Daniele Colombo, Gloria Padoani, Silvia Vailati, Noemi Aiezza, Alberto Antonelli, Selene Boncompagni, Tommaso Giani, Lucia Pallecchi, Gian Maria Rossolini, Maria Micieli
  • Safinamide for treating myotonia
    Patent number: 11707441
    Abstract: The present invention relates to safmamide or a pharmaceutically acceptable salt thereof for use in the treatment of a condition caused by pathological sarcolemma hyperexcitability, and/or of any other condition in which the restoration of normal sarcolemma excitability may produce a therapeutic benefit or improvement, wherein said condition is preferably a myotonic disorder.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: July 25, 2023
    Assignee: Zambon S.P.A.
    Inventors: Jean-François Desaphy, Sabata Pierno, Diana Conte, Elsa Melloni, Silvia Vailati, Gloria Padoani, Carla Caccia
  • SAFINAMIDE FOR TREATING MYOTONIA
    Publication number: 20210196657
    Abstract: The present invention relates to safmamide or a pharmaceutically acceptable salt thereof for use in the treatment of a condition caused by pathological sarcolemma hyperexcitability, and/or of any other condition in which the restoration of normal sarcolemma excitability may produce a therapeutic benefit or improvement, wherein said condition is preferably a myotonic disorder.
    Type: Application
    Filed: May 28, 2019
    Publication date: July 1, 2021
    Applicant: Zambon S.P.A.
    Inventors: Jean-François Desaphy, Sabata Pierno, Diana Conte, Elsa Melloni, Silvia Vailati, Gloria Padoani, Carla Caccia